Moberg Pharma strengthens the organization
STOCKHOLM, November 7[th], 2023, Moberg Pharma AB (OMX: MOB) is strengthening its organization following market approval earlier this year and in preparation for the upcoming launch. The management team is welcoming two new members, Christina Erixon, Head of Pharmaceutical Development & Operations, who is replacing Agneta Larhed, and Robert Ehrl, Head of Supply, who is taking over from Jesper Lind. Both roles have been expanded from part-time consultants to full-time positions.Agneta Larhed is leaving the executive team but will remain a part-time consultant to the company with unchanged